BioCryst Pharmaceuticals (BCRX) Competitors $7.57 +0.18 (+2.44%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BCRX vs. IONS, ALKS, FOLD, LGND, GERN, CLDX, MNKD, DVAX, NVAX, and MYGNShould you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Geron (GERN), Celldex Therapeutics (CLDX), MannKind (MNKD), Dynavax Technologies (DVAX), Novavax (NVAX), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry. BioCryst Pharmaceuticals vs. Ionis Pharmaceuticals Alkermes Amicus Therapeutics Ligand Pharmaceuticals Geron Celldex Therapeutics MannKind Dynavax Technologies Novavax Myriad Genetics Ionis Pharmaceuticals (NASDAQ:IONS) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership. Which has more risk & volatility, IONS or BCRX? Ionis Pharmaceuticals has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Is IONS or BCRX more profitable? BioCryst Pharmaceuticals has a net margin of -30.01% compared to Ionis Pharmaceuticals' net margin of -44.58%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ionis Pharmaceuticals-44.58% -88.98% -12.42% BioCryst Pharmaceuticals -30.01%N/A -24.06% Which has higher earnings and valuation, IONS or BCRX? BioCryst Pharmaceuticals has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIonis Pharmaceuticals$803.07M7.01-$366.29M-$2.44-14.60BioCryst Pharmaceuticals$412.58M3.80-$226.54M-$0.61-12.41 Do institutionals & insiders believe in IONS or BCRX? 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate IONS or BCRX? Ionis Pharmaceuticals currently has a consensus target price of $60.65, suggesting a potential upside of 70.21%. BioCryst Pharmaceuticals has a consensus target price of $15.60, suggesting a potential upside of 106.08%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Ionis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ionis Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.68BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the MarketBeat Community believe in IONS or BCRX? Ionis Pharmaceuticals received 212 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. However, 66.53% of users gave BioCryst Pharmaceuticals an outperform vote while only 60.28% of users gave Ionis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformIonis PharmaceuticalsOutperform Votes69560.28% Underperform Votes45839.72% BioCryst PharmaceuticalsOutperform Votes48366.53% Underperform Votes24333.47% Does the media refer more to IONS or BCRX? In the previous week, Ionis Pharmaceuticals had 9 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 14 mentions for Ionis Pharmaceuticals and 5 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.13 beat Ionis Pharmaceuticals' score of 0.76 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 3 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBioCryst Pharmaceuticals beats Ionis Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCRX vs. The Competition Export to ExcelMetricBioCryst PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.57B$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-12.4146.7391.3417.19Price / Sales3.80411.851,116.63116.80Price / CashN/A182.1042.5837.86Price / Book-3.413.894.794.78Net Income-$226.54M-$42.21M$120.07M$225.60M7 Day Performance0.53%-2.14%-1.90%-1.24%1 Month Performance0.87%4.21%11.43%3.06%1 Year Performance31.42%18.40%30.59%16.50% BioCryst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCRXBioCryst Pharmaceuticals3.7226 of 5 stars$7.57+2.4%$15.60+106.1%+34.2%$1.57B$412.58M-12.41530Positive NewsIONSIonis Pharmaceuticals4.4165 of 5 stars$38.46+5.1%$60.65+57.7%-26.3%$6.07B$803.07M-15.00800Analyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsALKSAlkermes4.6624 of 5 stars$30.76+0.8%$35.42+15.1%+9.3%$4.98B$1.51B15.652,100Positive NewsFOLDAmicus Therapeutics4.326 of 5 stars$9.90+5.8%$16.88+70.5%-23.7%$2.96B$493.67M-28.71480Analyst DowngradeLGNDLigand Pharmaceuticals4.9831 of 5 stars$123.60+5.7%$147.00+18.9%+65.4%$2.34B$152.42M47.4480Analyst RevisionGERNGeron3.8487 of 5 stars$3.79-1.8%$7.15+88.7%+61.6%$2.29B$29.48M-12.06141Short Interest ↓CLDXCelldex Therapeutics2.6773 of 5 stars$26.43+4.0%$62.25+135.5%-33.5%$1.75B$6.88M-9.89160Analyst ForecastNews CoveragePositive NewsMNKDMannKind3.199 of 5 stars$6.29-3.8%$8.67+37.8%+105.4%$1.73B$198.96M93.43400Analyst UpgradeAnalyst RevisionNews CoverageDVAXDynavax Technologies4.6677 of 5 stars$12.98+0.2%$22.00+69.5%-4.1%$1.71B$260.81M100.00408Positive NewsNVAXNovavax3.8281 of 5 stars$9.28+1.9%$17.83+92.2%+77.2%$1.49B$847.25M-4.031,543MYGNMyriad Genetics4.4467 of 5 stars$14.06-2.6%$24.27+72.6%-34.3%$1.28B$823.60M-11.102,700 Related Companies and Tools Related Companies IONS Competitors ALKS Competitors FOLD Competitors LGND Competitors GERN Competitors CLDX Competitors MNKD Competitors DVAX Competitors NVAX Competitors MYGN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCRX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
